Ike Swetlitz
-
Teva Pharmaceutical To Face FTC Investigation Over Patents
Teva Pharmaceutical Industries Ltd. is being investigated by the US Federal Trade Commission over patents for certain drugs including asthma inhalers, according to a person familiar with the matter.
- Monday July 1, 2024
- Author: Sabrina Willmer, Ike Swetlitz
-
J&J Pharma Sales Edge Out Street Estimates as Profit Beats
Johnson & Johnson’s first-quarter drug sales narrowly outpaced Wall Street expectations as the company beat profit estimates, a step towards boosting profitability after the spinoff of its consumer division.
- Tuesday April 16, 2024
- Author: Ike Swetlitz
-
J&J Pharma Sales Edge Out Street Estimates as Profit Beats
Johnson & Johnson’s first-quarter drug sales narrowly outpaced Wall Street expectations as the company beat profit estimates, a step towards boosting profitability after the spinoff of its consumer division.
- Tuesday April 16, 2024
- Author: Ike Swetlitz
-
Moderna Covid-19 Vaccine Protects Against New Variants In Early Study
The vaccine significantly boosted levels of antibodies that target the EG.5 and FL.1.5.1 variants, Moderna said in a statement
- Friday August 18, 2023
- Author: Ike Swetlitz
-
Vertex Falls After FDA Halts Diabetes Study in Surprise Move
Vertex Falls After FDA Halts Diabetes Study in Surprise Move
- Monday May 2, 2022
- Author: Catherine Larkin, Ike Swetlitz
-
Gilead Takes $2.7 Billion Writedown; Covid Drug Tops Estimates
Gilead Takes $2.7 Billion Writedown; Covid Drug Tops Estimates
- Friday April 29, 2022
- Author: Ike Swetlitz
-
‘Bizarre’ Potential $7.1 Billion Tax Bill Sinks Amgen Shares
‘Bizarre’ Potential $7.1 Billion Tax Bill Sinks Amgen Shares
- Friday April 29, 2022
- Author: Ike Swetlitz
-
More Cancers Are Being Detected in Later Stages at Top Boston Hospital
More Cancers Are Being Detected in Later Stages at Top Boston Hospital
- Friday April 22, 2022
- Author: Ike Swetlitz
-
Flagship-Backed Tessera Raises $300 Million for Gene-Fixing Tech
Flagship-Backed Tessera Raises $300 Million for Gene-Fixing Tech
- Friday April 22, 2022
- Author: Ike Swetlitz